- ICE and IVUS Industry is expected to register 5.2% CAGR between 2022 and 2028 driven by growing burden of cardiovascular disorders resulting to increasing procedural volume. SELBYVILLE
Obesity drugs had a good year, the SGLT2 inhibitors stalled, and Entresto looks less impressive these are some of the takes from John Mandrola, MD, in his annual review of cardiology research.